PhaseBio Pharmaceuticals IncOver The Counter Market:PHASQ
- LAST PRICE0.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
PhaseBio Pharmaceuticals Inc | 50.0 | 0.0x | --- |
Todos Medical Ltd | 2.1K | 0.0x | --- |
Rosetta Genomics Ltd | 590.0 | 0.0x | --- |
Medicure Inc | 8.0M | -12.3x | --- |
Pear Therapeutics Inc | 140.0 | 0.0x | --- |
TRACON Pharmaceuticals Inc | 4.1M | -0.3x | --- |
Company Information
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapies for cardiovascular diseases. Its lead product candidate, bentracimab (also known as PB2452), is a novel reversal agent for the antiplatelet drug ticagrelor. Ticagrelor is an antiplatelet therapy widely prescribed to reduce the rates of death, heart attack and stroke in patients with acute coronary syndrome (ACS), or who have previously experienced a heart attack. Ticagrelor binds to platelets to prevent them from forming blood clots that could restrict blood flow. The Company is also developing its preclinical product candidate, PB6440, an oral selective aldosterone synthase inhibitor for treatment-resistant hypertension. The Company is leveraging ELP biopolymer technology to evaluate additional preclinical and discovery-stage candidates. Its focus is on proteins and peptides that are scientifically or clinically validated.
Contact Information
- Headquarters
- 1 Great Valley Pkwy Ste 30MALVERN, PA, United States 19355-1423
- Phone
- 610-981-6500
- Fax
- 302-531-3150
Executives
- Independent Chairman of the Board, Co-Founder
- Clay Thorp
- Chief Executive Officer, Director
- Jonathan Mow
- Principal Financial Officer
- Lawrence Perkins
- Senior Vice President, General Counsel, Company Secretary
- Kristophe Hanson
- Senior Vice President of Human Resources
- Glen Burkhardt
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $50.00 |
|---|---|
Revenue (TTM) | $818.0K |
Shares Outstanding | 49.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.06 |
EPS | $-2.13 |
Book Value | $-1.93 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -12,738.63% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
